60Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Ukraine
Neuroscience Intelligence
Ukraine neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #49 of 50 · Data maturity A · Research score 26.6 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
10Recruiting trials
6Publications
4Institutions
Executive interpretation
Ukraine ranks #49 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC106 recruiting
AbbVie40 recruiting
Boehringer Ingelheim40 recruiting
GlaxoSmithKline30 recruiting
Novo Nordisk A/S30 recruiting
Celgene20 recruiting
Hoffmann-La Roche22 recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company21 recruiting
Eisai Limited20 recruiting
Forest Laboratories20 recruiting
Disease activity
Parkinsons16trials
Epilepsy13trials
Schizophrenia6trials
Depression5trials
Alzheimers4trials
Multiple Sclerosis4trials
Autism2trials
Neuromuscular1trials
Pain Neuropathy1trials
Bipolar Disorder1trials
Research institutions
Institute of Neurology, Psychiatry and NarcologyOpenAlexlinked institution
National Academy of Medical Sciences of UkraineOpenAlexlinked institution
Shupyk National Healthcare University of UkraineOpenAlexlinked institution
Vasyl Stefanyk Carpathian National UniversityOpenAlexlinked institution
Clinical evidence trail
NCT07252739KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06788912Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)RECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05123703A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)ACTIVE_NOT_RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT04544436A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)ACTIVE_NOT_RECRUITING
NCT04165798KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)RECRUITING
NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)ACTIVE_NOT_RECRUITING
NCT05514535A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)COMPLETED
NCT05485116The Influence of Therapeutic Tactics of Analgesia on the Long-term Results of Pain Treatment in Patients With Gunshot and Mine-explosive WoundsCOMPLETED
Research evidence trail
PUBMEDEfficacy and cardiovascular safety of lasmiditan in patients with cardiovascular risk factors: A systematic review and meta-analysis with updated synthesis of triptan safety data.2026-10-01
PUBMEDNeurocognitive consequences of blast injuries in military personnel with mild traumatic brain injury: evaluation with the ImPACT quick test.2026-09-22
PUBMEDAge- and sex-dependent effects of single prolonged stress on behavioral, hematological, and oxidative stress parameters in C57BL/6J mice.2026-09-11
PUBMEDAn Augmented Reality-Based Concept for Anchor-Free Assessment of Tremor-Related Hand Movement Patterns.2026-09-07
PUBMEDCeftriaxone has a similar effect on astrocytic and neuronal GLT-1 distribution after mild traumatic brain injury.2026-07-16
OPENALEXGlutathione Homeostasis and Functions: Potential Targets for Medical Interventions2012-02-28
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.